Effect of serine protease inhibitor Kazaltype 1 on the proliferation of
hepatocellular carcinoma cell and its mechanism

ZHAO Wei-Ming; YU Guo-Ying; WANG Gai-Ping; CHANG Cui-Fang

doi:10.16098/j.issn.0529-1356.2023.06.011

PDF(2832 KB)

Acta Anatomica Sinica ›› 2023, Vol. 54 ›› Issue (6) : 695-702. DOI: 10.16098/j.issn.0529-1356.2023.06.011

Effect of serine protease inhibitor Kazaltype 1 on the proliferation of hepatocellular carcinoma cell and its mechanism

ZHAO Wei-ming LI Xiao YU Guo-ying WANG Gai-ping CHANG Cui-fang*

Author information +

History +

Abstract

Objective To explore the effect of serine protease inhibitor Kazal-type 1(SPINK1) on the proliferation of hepatocellular carcinoma cells RH-35 and its underling molecular mechanism. Methods Spink1 gene expression in liver cancer and rat liver cancer models were analyzed by Gene Expression Omnibus (GEO) data, RH-35 cells were treated with rrSPINK1 protein, the effect of rrSPINK1 on the proliferation and apoptosis of RH-35 cells was explored by MTT, 2’-deoxy-5-ethynyluridine(EdU) and flow cytometry, the molecular mechanism of SPINK1 regulating liver cancer were detected by Real-time PCR and Western blotting. Results The results showed that Spink1 gene was over-expressed significantly in liver cancer and rat liver cancer models, rrSPINK1-treated RH-35 cells showed increased viability, EdU-positive cell rate, and the proportion of cells in S phase and G2/M phase compared to the control group. However, there was no significant difference in RH-35 cell apoptosis. rrSPINK1 up-regulated the expression of p38 MAPK and STAT pathway-related genes/proteins in RH-35 cells; and the expression of Spink1 gene in liver cancer was positively correlated with that of Mpak13, Stat1 and Stat3 genes. Conclusion SPINK1 may promote the expression of p38 MAPK and Januk kinase/signal transducers and activators of transcription(JAK/STAT), and promote the proliferation of hepatocellular carcinoma cells.

Key words

Serine protease inhibitor Kazal-type 1 / Liver cancer / Cell proliferation / Flow cytometry / Human / Rat

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHAO Wei-ming LI Xiao YU Guo-ying WANG Gai-ping CHANG Cui-fang.

Effect of serine protease inhibitor Kazaltype 1 on the proliferation of hepatocellular carcinoma cell and its mechanism

[J]. Acta Anatomica Sinica. 2023, 54(6): 695-702 https://doi.org/10.16098/j.issn.0529-1356.2023.06.011

References

［1］Lu ChCh, Huang YY, XU LY, et al. Up-regulation of serine protease inhibitor Kazal type 1 expression in human lung adenocarcinoma and promotion of proliferation of cancer cells ［J］. Acta Anatomica Sinica, 2019, 50(2):192-200. (in Chinese)

陆畅畅，黄燕燕，续力云，等. 丝氨酸蛋白酶抑制因子Kazal 1型在人肺腺癌组织表达上调并促进肺腺癌细胞的增殖［J］. 解剖学报，2019，50(2)：192-200.

［2］Li F, Liu T, Xiao CY, et al. FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection ［J］. Biomed Pharmacother, 2015, 72:103-108.

［3］Hass HG, Jobst J, Vogel U, et al. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis ［J］. Oncol Res Treat, 2014, 37(12):732-738.

［4］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 ［J］. CA Cancer J Clin, 2016, 66(2):115-132.

［5］Rasanen K, Itkonen O, Koistinen H, et al. Emerging roles of SPINK1 in cancer［J］. Clin Chem, 2016, 62(3):449-457.

［6］Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants［J］. Chin Med J (Engl), 2022, 135(5):584-590.

［7］Zhu C, Han H, Li J, et al. Hepatitis B virus X protein induced serine protease inhibitor kazal type 1 is associated with the progression of HBV-related diseases［J］. Biomed Res Int, 2019, 2019:9321494.

［8］Huang K, Xie W, Wang S, et al. High SPINK1 expression predicts poor prognosis and promotes cell proliferation and metastasis of hepatocellular carcinoma ［J］. J Invest Surg, 2021, 34(9):1011-1020.

［9］Mehner C, Radisky ES. Bad tumors made worse: SPINK1 ［J］. Front Cell Dev Biol, 2019, 7:10.

［10］Lin S, Lin Y, Wu Z, et al. circRPS16 promotes proliferation and invasion of hepatocellular carcinoma by sponging miR-876-5p to upregulate SPINK1 ［J］. Front Oncol, 2021, 11:724415.

［11］Guo M, Zhou X, Han X, et al. SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis ［J］. Oncol Lett, 2019, 18(6):6899-6908.

［12］Chang C, Zhao W, Luo Y, et al. Serine peptidase inhibitor Kazal type I (SPINK1) promotes BRL-3A cell proliferation via p38, ERK, and JNK pathways ［J］. Cell Biochem Funct, 2017, 35(6):339-348.

［13］Wang LL, Luo J, He ZH, et al. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma［J］. Cell Death Dis, 2021, 12(11):1052.

［14］Kim H, Lim HY. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways［J］. J Korean Med Sci, 2011, 26(12):1563-1568.

［15］Kannangai R, Sahin F, Torbenson MS. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma ［J］. Mod Pathol, 2006, 19(11):1456-1461.

［16］Yamada K, Kizawa R, Yoshida A, et al. Extracellular PKCdelta signals to epidermal growth factor receptor for tumor proliferation in liver cancer cells ［J］. Cancer Sci, 2022, 113(7):2378-2385.

［17］Chang CF, Yang J, Li XF, et al. SPINK3: A novel growth factor that promotes rat liver regeneration［J］. Mol Biol (Mosk), 2016, 50(3):457-465.

［18］Zhang Z, Pan Y, Zhao Y, et al. Delphinidin modulates JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells［J］. Environ Toxicol, 2021, 36(8):1557-1566.

［19］Okabe N, Fujiwara M, Tachibana K, et al. STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior［J］. Gen Thorac Cardiovasc Surg, 2021, 69(11):1482-1491.

［20］Huth HW, Albarnaz JD, Torres AA, et al. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression［J］. Cell Signal, 2016, 28(9):1283-1291.